Related Experiment Videos

Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture

Cancer Research
|April 1, 1984
PubMed

Insights

Antiestrogens like tamoxifen halt breast cancer cell cycle progression in G1 phase. Estrogen can reverse this effect, promoting cell cycle reentry and offering insights for combined chemoendocrine therapy strategies.

Area of Science:

  • Endocrinology
  • Cell Biology
  • Oncology

Background:

  • Estrogens and antiestrogens significantly influence breast cancer growth through mechanisms not fully understood.
  • Tamoxifen, a common antiestrogen, was previously shown to delay cell cycle transition in early to mid-G1 phase.

Purpose of the Study:

  • To investigate the cell cycle kinetic effects of estrogens and antiestrogens on cultured human breast cancer cell lines.
  • To determine the dose-dependency of tamoxifen's cell cycle effects and compare them with other antiestrogens.
  • To explore the reversal of antiestrogen-induced cell cycle arrest by estrogen.

Main Methods:

  • Cultured human breast cancer cell lines (MCF-7, ZR75-1, MDA-231) were treated with varying concentrations of tamoxifen, nafoxidine, trioxifene, and 17 beta-estradiol.
  • Cell cycle kinetics were analyzed by monitoring the distribution of cells in G1, S, and G2+M phases.
  • Reversal experiments involved changing medium or adding estradiol to tamoxifen-treated cells.

Main Results:

  • Tamoxifen, nafoxidine, and trioxifene demonstrated dose-dependent G1 cell cycle arrest in estrogen receptor-positive cell lines (MCF-7, ZR75-1).
  • 17 beta-estradiol effectively reversed the G1 block induced by antiestrogens, causing cells to re-enter the S phase.
  • These effects were mediated through the estrogen receptor, as no impact was observed in estrogen receptor-negative MDA-231 cells.

Conclusions:

  • Antiestrogens induce a prominent accumulation of cells in the G1 phase of the cell cycle in endocrine-dependent breast cancer cells.
  • Estrogen can reverse this antiestrogen-induced G1 block, facilitating synchronous cell cycle progression.
  • These findings are crucial for designing effective clinical trials combining chemotherapy and endocrine therapy for breast cancer.

Related Concept Videos